Carcinoma In Situ — Trials

Carcinoma In Situ — Trials · CancerIndex

Clinical trials

Registered studies

274 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 72
Recruiting: 35
Ph III recruiting: 4
Growth YoY: —
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (41)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06843681	Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study	enrolling by invitation	Phase 2	54	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER	1	Nov 28, 2025	clinicaltrials
NCT04755517	Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)(HPV400)	enrolling by invitation	N/A	14,000	Tampere University HospitalOTHER	1